Advertisement
Table 3 Patterns of disease progression and subsequent outcomes
| Characteristics | n = 90 |
|---|---|
| PD | 57 (63) |
| RECIST | 51 (89) |
| Clinical | 5 (9) |
| Both | 1 (2) |
| Patients with new organ sites at time of RECIST PD | 23 (44) |
| New organ sites at time of RECIST PD | |
| Brain | 8 (35) |
| Bones | 1 (4) |
| Liver | 4 (17) |
| Soft tissue | 4 (17) |
| Pleural | 1 (4) |
| Local | 4 (17) |
| Adrenal | 3 (13) |
| Management after PD | |
| Subsequent systemic treatment | 28 (49) |
| Hospice | 23 (40) |
| Died | 3 (5) |
| Subsequent therapies in PD group after nivolumab discontinued | |
| Cabozantinib | 6 (21) |
| Axitinib | 14 (50) |
| Everolimus | 1 (4) |
| Temsirolimus | 3 (11) |
| Sunitinib | 2 (7) |
| Others* | 2 (7) |
